Richard Branson SPAC may help take 23andMe public at $4B valuation

A "blank check" merger at a $4 billion valuation may be in the future for consumer genetics testing unicorn 23andMe Inc. Bloomberg and Financial Times both cited unnamed sources on Wednesday who said the Sunnyvale company led by Anne Wojcicki is in talks with New York-based VG Acquisition Corp., a special purpose acquisition company (SPAC) backed by Richard Branson's Virgin Group Ltd. The SPAC's stock (NYSE:VGAC) j umped by 18% on the news on Wednesday before trading was halted temporarily. It finished…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news